Zhao FH, Wu T, Hu YM, Wei LH, et al. Efficacy, safety, and immunogenicity of an Escherichia coli-produced Human Papillomavirus (16 and 18) L1 virus-like-particle vaccine: end-of-study analysis of a phase 3, double-blind, randomised, controlled trial. Lancet Infect Dis 2022 Aug 26. pii: S1473-3099(22)00435.
PMID: 36037823